Romosozumab-aqqg (Evenity™)

Coverage: Romosozumab‑aqqg (Evenity) is covered only for postmenopausal women at high risk for fracture (not for men or low‑risk women) and is limited to a single 12‑month course (≤12 monthly doses). Key requirements: approval requires documentation of osteoporosis plus fracture history or qualifying BMD (T ≤ −2.5 or T between −1.0 and −2.5 with high fracture risk), evidence of prior IV bisphosphonate or a 12‑month oral bisphosphonate trial with failure/intolerance or documented contraindication to oral bisphosphonates, relevant renal function data (e.g., CrCl if claiming severe impairment), and compliance with applicable safety criteria.

"Safety criteria referenced but not detailed in this document (use restricted to meeting applicable safety criteria)."

Sign up to see full coverage criteria, indications, and limitations.